

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

SUPPLEMENTAL ANNOUNCEMENT

INSIDE INFORMATION

PROFIT WARNING

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司*) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the Company’s profit warning announcement dated 6 November 2020 in respect of the draft unaudited consolidated management accounts of the Group for the six-month period ended 30 September 2020 (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

The Board wishes to update the shareholders and potential investors of the Company that based on the preliminary assessment of the Board after reviewing the draft unaudited consolidated management accounts of the Group for the six-month period ended 30 September 2020 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the Company of not less than HK\$200 million for the six-month period ended 30 September 2020 as compared with a profit attributable to owners of the Company of approximately HK\$32 million recorded for the corresponding period in 2019. Such expected loss is mainly attributable to, among other things, the loss resulting from the disposal of the Group’s investment in Easy One Financial Group Limited, an associate of the Company, after period end which was measured at fair value less costs and such valuation is lower than their carrying amounts and the absence of material gain on disposal of items of property, plant and equipment and an investment property as recorded in the corresponding period in 2019.

*For identification purpose only

As the Company is still in the course of finalising its interim results for the six-month period ended 30 September 2020, the information contained in this announcement is solely based on the preliminary assessment by the Board after reviewing the draft unaudited consolidated management accounts of the Group for the six-month period ended 30 September 2020 which have yet to be finalised. Details of the performance of the Company for the six-month period ended 30 September 2020 will be disclosed in the interim results announcement of the Company, which is expected to be published by the end of November 2020 in accordance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Chan Chun Hong, Thomas
Managing Director

Hong Kong, 11 November 2020

As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas, Ms. Tang Mui Fun and Ms. Tang Wai Man, and the independent non-executive directors of the Company are Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.